| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Medicine, Cork University Hospital, and
Department of Surgery, Mercy Hospital, National University of Ireland, Cork, Ireland
Various cancer cell lines express Fas ligand (FasL) and can kill lymphoid cells by Fas-mediated apoptosis in vitro. FasL expression has been demonstrated in several human malignancies in vivo. We sought to determine whether human esophageal carcinomas express FasL, and whether FasL expression is associated with increased apoptosis of tumor-infiltrating lymphocytes (TIL) in vivo, thereby contributing to the immune privilege of the tumor. Using in situ hybridization and immunohistochemistry, respectively, FasL mRNA and protein were colocalized to neoplastic esophageal epithelial cells in all esophageal carcinomas (squamous, n = 6; adenocarcinoma, n = 2). The Extent of FasL expression was variable, with both FasL-positive and FasL-negative neoplastic regions occurring within tumors. TIL were detected by immunohistochemical staining for the leukocyte common Ag, CD45. FasL expression was associated with a mean fourfold depletion of TIL when compared with FasL-negative areas within the same tumors (range 1.6- to 12-fold, n = 6, p < 0.05). Cell death of TIL was detected by dual staining of CD45 (immunohistochemistry) and DNA strand breaks (TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling). There was a mean twofold increase in detectable cell death among TIL in FasL-positive areas compared with FasL-negative areas (range 1.6- to 2.4-fold, n = 6, p < 0.05). In conclusion, we demonstrate a statistically significant, quantitative reduction of TIL concomitant with significantly increased TIL apoptosis within FasL-expressing areas of esophageal tumors. Our findings suggest Fas-mediated apoptotic depletion of TIL in response to FasL expression by esophageal cancers, and provide the first direct, quantitative evidence to support the Fas counterattack as a mechanism of immune privilege in vivo in human cancer.
This article has been cited by other articles:
|
|
 |
|
  T. Das, G. Sa, E. Paszkiewicz-Kozik, C. Hilston, L. Molto, P. Rayman, D. Kudo, K. Biswas, R. M. Bukowski, J. H. Finke, et al. Renal Cell Carcinoma Tumors Induce T Cell Apoptosis through Receptor-Dependent and Receptor-Independent Pathways J. Immunol., April 1, 2008; 180(7): 4687 - 4696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zhang, T. Sun, L. Xue, X. Han, B. Zhang, N. Lu, Y. Shi, W. Tan, Y. Zhou, D. Zhao, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer Carcinogenesis, May 1, 2007; 28(5): 1067 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jewett, C. Head, and N.A. Cacalano Emerging Mechanisms of Immunosuppression in Oral Cancers Journal of Dental Research, December 1, 2006; 85(12): 1061 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K W Chan, P Y Lee, A K Y Lam, S Law, J Wong, and G Srivastava Clinical relevance of Fas expression in oesophageal squamous cell carcinoma J. Clin. Pathol., January 1, 2006; 59(1): 101 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Ryan, F. Shanahan, J. O'Connell, and A. M. Houston Addressing the "Fas Counterattack" Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer In vivo Cancer Res., November 1, 2005; 65(21): 9817 - 9823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sun, Y. Zhou, H. Li, X. Han, Y. Shi, L. Wang, X. Miao, W. Tan, D. Zhao, X. Zhang, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer J. Exp. Med., October 3, 2005; 202(7): 967 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X Zhang, X Miao, T Sun, W Tan, S Qu, P Xiong, Y Zhou, and D Lin Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer J. Med. Genet., June 1, 2005; 42(6): 479 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Wolkersdorfer, C. Marx, J. Brown, S. Schroder, M. Fussel, E. P. Rieber, E. Kuhlisch, G. Ehninger, and S. R. Bornstein Prevalence of HLA-DRB1 Genotype and Altered Fas/Fas Ligand Expression in Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1768 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Bohana-Kashtan and C. I. Civin Profiling Tumor Counterattack: Do Fas Ligand-Containing Microvesicles Reduce Anticancer Immunity? Clin. Cancer Res., February 1, 2005; 11(3): 968 - 970. [Full Text] [PDF]
|
|
|
|
|
|
F. Donskov, H. von der Maase, N. Marcussen, S. Hamilton-Dutoit, H. H. T. Madsen, J. J. Jensen, and M. Hokland Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy: No In vivo Effect of Fas Ligand Tumor Counterattack Clin. Cancer Res., December 1, 2004; 10(23): 7911 - 7916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hallermalm, A. De Geer, R. Kiessling, V. Levitsky, and J. Levitskaya Autocrine Secretion of Fas Ligand Shields Tumor Cells from Fas-Mediated Killing by Cytotoxic Lymphocytes Cancer Res., September 15, 2004; 64(18): 6775 - 6782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression Clin. Cancer Res., August 1, 2004; 10(15): 5094 - 5100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sun, X. Miao, X. Zhang, W. Tan, P. Xiong, and D. Lin Polymorphisms of Death Pathway Genes FAS and FASL in Esophageal Squamous-Cell Carcinoma J Natl Cancer Inst, July 7, 2004; 96(13): 1030 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Longley, W. L. Allen, U. McDermott, T. R. Wilson, T. Latif, J. Boyer, M. Lynch, and P. G. Johnston The Roles of Thymidylate Synthase and p53 in Regulating Fas-Mediated Apoptosis in Response to Antimetabolites Clin. Cancer Res., May 15, 2004; 10(10): 3562 - 3571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schneider-Stock, C. Mawrin, C. Motsch, C. Boltze, B. Peters, R. Hartig, P. Buhtz, A. Giers, A. Rohrbeck, B. Freigang, et al. Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer Am. J. Pathol., April 1, 2004; 164(4): 1233 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Reichert, L. Strauss, E. M. Wagner, W. Gooding, and T. L. Whiteside Signaling Abnormalities, Apoptosis, and Reduced Proliferation of Circulating and Tumor-infiltrating Lymphocytes in Patients with Oral Carcinoma Clin. Cancer Res., October 1, 2002; 8(10): 3137 - 3145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Igney and P. H. Krammer Immune escape of tumors: apoptosis resistance and tumor counterattack J. Leukoc. Biol., June 1, 2002; 71(6): 907 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Andreola, L. Rivoltini, C. Castelli, V. Huber, P. Perego, P. Deho, P. Squarcina, P. Accornero, F. Lozupone, L. Lugini, et al. Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles J. Exp. Med., May 20, 2002; 195(10): 1303 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jodo, S. Xiao, A. Hohlbaum, D. Strehlow, A. Marshak-Rothstein, and S.-T. Ju Apoptosis-inducing Membrane Vesicles. A NOVEL AGENT WITH UNIQUE PROPERTIES J. Biol. Chem., October 19, 2001; 276(43): 39938 - 39944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ni, P. Hazarika, C. Zhang, R. Talpur, and M. Duvic Fas Ligand Expression by Neoplastic T Lymphocytes Mediates Elimination of CD8+ Cytotoxic T Lymphocytes in Mycosis Fungoides: A Potential Mechanism of Tumor Immune Escape? Clin. Cancer Res., September 1, 2001; 7(9): 2682 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen and C. S. Yang Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention Carcinogenesis, August 1, 2001; 22(8): 1119 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zagury, A. Burny, and R. C. Gallo Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines PNAS, July 3, 2001; 98(14): 8024 - 8029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Radoja, M. Saio, and A. B. Frey CD8+ Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ J. Immunol., May 15, 2001; 166(10): 6074 - 6083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Behrens, F. H. Igney, B. Arnold, P. Moller, and P. H. Krammer CD95 Ligand-Expressing Tumors Are Rejected in Anti-Tumor TCR Transgenic Perforin Knockout Mice J. Immunol., March 1, 2001; 166(5): 3240 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Gastman, X.-M. Yin, D. E. Johnson, E. Wieckowski, G.-Q. Wang, S. C. Watkins, and H. Rabinowich Tumor-induced Apoptosis of T Cells: Amplification by a Mitochondrial Cascade Cancer Res., December 1, 2000; 60(24): 6811 - 6817. [Abstract] [Full Text]
|
|
|
|
|
|
M. Shibakita, M. Tachibana, D. K. Dhar, S. Ohno, H. Kubota, H. Yoshimura, S. Kinugasa, R. Masunaga, and N. Nagasue Spontaneous Apoptosis in Advanced Esophageal Carcinoma: Its Relation to Fas Expression Clin. Cancer Res., December 1, 2000; 6(12): 4755 - 4759. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. Reed Mechanisms of Apoptosis Am. J. Pathol., November 1, 2000; 157(5): 1415 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Yakes, B. D. Wamil, F. Sun, H.-P. Yan, C. E. Carter, and C. G. Hellerqvist CM101 Treatment Overrides Tumor-induced Immunoprivilege Leading to Apoptosis Cancer Res., October 1, 2000; 60(20): 5740 - 5746. [Abstract] [Full Text]
|
|
|
|
|
|
K. Okada, K. Komuta, S. Hashimoto, S. Matsuzaki, T. Kanematsu, and T. Koji Frequency of Apoptosis of Tumor-infiltrating Lymphocytes Induced by Fas Counterattack in Human Colorectal Carcinoma and Its Correlation with Prognosis Clin. Cancer Res., September 1, 2000; 6(9): 3560 - 3564. [Abstract] [Full Text]
|
|
|
|
|
|
T. S. Griffith, R. D. Anderson, B. L. Davidson, R. D. Williams, and T. L. Ratliff Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis J. Immunol., September 1, 2000; 165(5): 2886 - 2894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I TINHOFER, H WYKYPIEL, I MARSCHITZ, T HENN, R GREIL;, M W BENNETT, J O'CONNELL, D ROCHE, C BRADY, J KELLY, et al. Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway • Reply Gut, May 1, 2000; 46(5): 738 - 740. [Full Text] [PDF]
|
|
|
|
|
|
A.-K. Eerola, Y. Soini, and P. Paakko A High Number of Tumor-infiltrating Lymphocytes Are Associated with a Small Tumor Size, Low Tumor Stage, and a Favorable Prognosis in Operated Small Cell Lung Carcinoma Clin. Cancer Res., May 1, 2000; 6(5): 1875 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Hohlbaum, S. Moe, and A. Marshak-Rothstein Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival J. Exp. Med., April 3, 2000; 191(7): 1209 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Gastman, D. E. Johnson, T. L. Whiteside, and H. Rabinowich Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events Blood, March 15, 2000; 95(6): 2015 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Reimer, C. Herrnring, D. Koczan, D. Richter, B. Gerber, D. Kabelitz, K. Friese, and H.-J. Thiesen FasL:Fas Ratio-A Prognostic Factor in Breast Carcinomas Cancer Res., February 1, 2000; 60(4): 822 - 828. [Abstract] [Full Text]
|
|
|
|
|
|
B. R. Gastman, Y. Atarashi, T. E. Reichert, T. Saito, L. Balkir, H. Rabinowich, and T. L. Whiteside Fas Ligand Is Expressed on Human Squamous Cell Carcinomas of the Head and Neck, and It Promotes Apoptosis of T Lymphocytes Cancer Res., October 1, 1999; 59(20): 5356 - 5364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Bukowski, P. Rayman, L. Molto, C. S. Tannenbaum, T. Olencki, D. Peereboom, R. Tubbs, D. McLain, G. T. Budd, T. Griffin, et al. Interferon-{{gamma}} and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma Clin. Cancer Res., October 1, 1999; 5(10): 2780 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reed Dysregulation of Apoptosis in Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2941 - 2941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shibakita, M. Tachibana, D. K. Dhar, T. Kotoh, S. Kinugasa, H. Kubota, R. Masunaga, and N. Nagasue Prognostic Significance of Fas and Fas Ligand Expressions in Human Esophageal Cancer Clin. Cancer Res., September 1, 1999; 5(9): 2464 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O'Connell, M. W. Bennett, G. C. O'Sullivan, J. O'Callaghan, J. K. Collins, and F. Shanahan Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune Privilege Clin. Vaccine Immunol., July 1, 1999; 6(4): 457 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Pettersen, K. Hestdal, M. K. Olafsen, S. O. Lie, and F. P. Lindberg CD47 Signals T Cell Death J. Immunol., June 15, 1999; 162(12): 7031 - 7040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shimizu, A. Fontana, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa Induction of Antitumor Immunity with Fas/APO-1 Ligand (CD95L)-Transfected Neuroblastoma Neuro-2a Cells J. Immunol., June 15, 1999; 162(12): 7350 - 7357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saito, I. Kuss, G. Dworacki, W. Gooding, J. T. Johnson, and T. L. Whiteside Spontaneous ex Vivo Apoptosis of Peripheral Blood Mononuclear Cells in Patients with Head and Neck Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1263 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Uzzo, P. Rayman, V. Kolenko, P. E. Clark, T. Bloom, A. M. Ward, L. Molto, C. Tannenbaum, L. J. Worford, R. Bukowski, et al. Mechanisms of Apoptosis in T Cells from Patients with Renal Cell Carcinoma Clin. Cancer Res., May 1, 1999; 5(5): 1219 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yu, K. Israel, Q. Y. Liao, C. M. Aldaz, B. G. Sanders, and K. Kline Vitamin E Succinate (VES) Induces Fas Sensitivity in Human Breast Cancer Cells: Role for Mr 43,000 Fas in VES-triggered Apoptosis Cancer Res., February 1, 1999; 59(4): 953 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M W Bennett, J O'Connell, G C O'Sullivan, D Roche, C Brady, J Kelly, J K Collins, and F Shanahan Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer Gut, February 1, 1999; 44(2): 156 - 162. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
